Effects of safinamide mesylate on neuroplasticity in patients with Parkinson's disease

Hanajima Ritsuko0 个研究点目标入组 30 人开始时间: 2022年11月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•[Parkinson's disease group]
•1) Patients diagnosed with Parkinson's disease according to the diagnostic criteria of the Parkinson's disease clinical practice guidelines 2018
•2) Patients considering initiation of safinamide mesilate concomitant administration in routine practice
•3) Patients between the ages of 20 and 90
•[Healthy volunteer group]
•1) Subjects who are age- and sex-matched with those enrolled in the Parkinson's disease group
•2) Subjects who are judged to be in good health by the investigator or co-investigator, with no abnormalities in subjective symptoms or objective findings in examinations and observations at the start of the study.

•[Parkinson's disease group]
•1) Patients with contraindications to safinamide mesylate
•2) Patients with safety risks associated with transcranial magnetic stimulation
•3) Patients judged to require administration of other Parkinson's disease drugs from the levodopa monotherapy period (from the time of informed consent) to the completion of the safinamide mesilate combination period. Patients receiving anticholinergics or amantadine hydrochloride could be enrolled if the dosage is not changed during the study.
•[Healthy volunteer group]
•1) Subjects with safety risks associated with transcranial magnetic stimulation
•2) Illicit drug users or alcoholics
•3) Subjects with a history or symptoms of neurological/psychiatric disorders
•4) Subjects who take medication for neurological/psychiatric disorders
•5) Subjects with serious illness

发起方

Hanajima Ritsuko